De Wit 1998.

Methods	A single‐centre study done at the reference hospital of Saint Pierre, Brussels, Belsgium Loss to follow‐up: Fluconazole ‐ 0/20 (0%) Ictraconazole ‐ 3/20 (15%) Analysis: no ITT No dates for start or end of study reported.
Participants	Inclusion criteria: 16‐65 years; AIDS / AIDS‐related complex, who are able to take oral medication; OPC suspected on clinical grounds Exclusion criteria: received antifungal treatment within 1 week before enrolment; or maintenance azole treatment for prevention of OPC during previous month; hepatic or renal disease; allergy to azole compounds or if they had had more than three OPC episodes during previous 2 months; end stage AIDS; fever of unknown origin; documented systemic fungal infections; any other acute concomitant infection; pregnancy and lactation. 40 enrolled Fluconazole =20 Ictraconazole = 20 diagnosis confirmed KOH and culture
Interventions	Fluconazole ‐ 150 mg stat Intraconazole ‐ 100 mg daily for 7 days
Outcomes	Clinical Cure : Signs and symptoms of OPC were graded on scale from 0 (absent) to 3 (severe). Symptoms and signs included soreness, burning or pain, dysphagia, erythema, and presence of white plaques. Extent of lesions present was graded on a scale of 0 (no lesions) to 4 (lesions covering more than 70% of oral mucosa). These scores were combined to give an overall clinical score. Clinical cure was defined as disappearance of all symptoms (clinical score = 0), improvement defined as clinical score lower than baseline score and failure as no change in clinical score or worsening of clinical symptoms. Relapse: defined as initial improvement or cure followed by reappearance of symptoms within 30 days after baseline examination. Mycological evaluation: eradication was defined as recovery of less than 10 colony forming units (CFUs)/ml, improvement as a count below baseline count but above 10 CFUs/ml and failure as an increase or no change. Adverse events: none reported
Notes	Ethics: Written informed consent obtained
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Method not specified
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	High risk	No blinding
Incomplete outcome data addressed? All outcomes	Low risk	3/20 lost to follow‐up in itraconazole group ‐ reasons provided.